Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prucalopride - Takeda

Next Previous
Search
Drug Profile

Prucalopride - Takeda

Alternative Names: Motegrity; Prucalopride succinate - Takeda; R 093877; R 108512; R 93877; Resolor; Resotran; Resotrans; Rezolor; SHP555; SPD-555; TAK-555

Latest Information Update: 04 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen
  • Developer Janssen; Shire-Movetis NV; Takeda; University of Calgary
  • Class Amides; Benzofurans; Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II/III Diabetic gastroparesis
  • No development reported Postoperative ileus

Most Recent Events

  • 22 Dec 2023 Takeda terminates a phase III trial for Constipation (In infants, In children, In adolescents) in USA (PO) due to the Data Monitoring Committe (DMC) decision; due to futility, with no safety concerns; FDA agreement to terminate the study (NCT04759833)
  • 12 Jul 2021 Takeda initiates phase III trial for Constipation (In infants, In children, In adolescents) in USA (PO) (NCT04759833)
  • 13 Apr 2021 Takeda plans a phase III trial for Constipation (PO, tablet) in May 2021 (NCT04838522)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top